乳癌，細胞凋亡，癌症疫苗:藥物開發策略分析 是由出版商BioSeeker Group AB在2011年12月所出版的。
這份英文市場調查報告書包含3189 Pages 價格從美金5175起跳。
本報告以乳癌的藥物開發策略和細胞凋亡及癌症疫苗的機制、目標、影響領域為焦點，彙整各種的藥劑目標策略，化合物策略競爭基準，開發平台及最佳投資組合計劃等資料，為您概述為以下內容。
第1章 乳癌
- 本報告的範圍
- 為達成最高治療效果及投資報酬率的乳癌治療目標
- 新藥的上市:乳癌治療藥物開發平台上指定的藥劑目標是否成熟，是否有特色，臨床評估如何
- 使用中的化合物策略:乳癌治療藥物各化合物策略競爭基準
- 開發平台及最佳投資組合計劃:乳癌治療開發平台的競爭基準
- 藥品目錄
- 企業目錄
- 圖表
第2章 細胞凋亡
- 本報告的範圍
- 為達成最高治療效果及投資報酬率的治療目標檢討
- 新藥的上市:細胞凋亡治療開發平台上指定的藥劑目標是否成熟，是否有特色，臨床評估如何
- 使用中的化合物策略:細胞凋亡藥物的各類型化合物的競爭基準
- 細胞凋亡的癌適應症症狀選擇
- 最佳投資組合計劃:細胞凋亡開發平台的競爭基準
- 藥品目錄
- 企業目錄
- 圖表
第3章 癌症疫苗
- 本報告的範圍
- 為達成最高治療效果及投資報酬率的治療目標檢討
- 新藥的上市:各開發階段的癌症疫苗治療藥劑目標策略
- 使用中的化合物策略:各化合物策略競爭基準
- 癌症疫苗的癌適應症症狀選擇
- 開發平台及最佳投資組合:癌症疫苗開發平台的競爭基準
- 免責聲明
- 藥品目錄
- 企業目錄
- 圖表
Abstract
Product Description
This triple analysis focuses on cancer drug development strategies in Breast
Cancer and by the two mechanism/target/effect areas of Apoptosis and Cancer
Vaccines. Each of these three individual parts is evaluated according to
standardized criteria in a five pillar pipeline drug assessment methodology to
compare drug development strategies in oncology. This makes it easy to find
and compare analysis not only within one single cancer focus area but also
between different areas.
Below is a short synopsis of each part included in this report:
Part I: Breast Cancer
The breast cancer report part comprises defined and up to date development
strategies for 405 breast cancer drugs within the portfolio of 220
investigators, from Ceased to Marketed. This report part extensively analyses
207 identified targets of breast cancer drugs, organized into 193 drug target
strategies, and assesses them in breast cancer.
Part II: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date
development strategies for 234 drugs in oncology within the portfolio of 158
companies world-wide, from Ceased to Marketed. The report extensively analyses
their 181 identified drug targets, organized into 157 drug target strategies,
and assesses them in 69 cancer indications.
Part III: Cancer Vaccines
The cancer vaccine report part comprises defined and up to date development
strategies for 155 cancer vaccine drugs within the portfolio of 99
investigators, from Ceased to Marketed. This part extensively analyses their
94 identified drug targets, organized into 91 drug target strategies, and
assesses them in 42 different cancer indications.
The report is written for you to understand and assess the impact of
competitor entry and corresponding changes to development strategies for your
own portfolio products. It helps teams to maximize molecule value by selecting
optimal development plans and manage risk and uncertainty. The report serves
as an external commercial advocate for pharmaceutical companies' pipeline and
portfolio planning (PPP) in cancer by:
- Providing you with competitive input to the R&D organization to guide
development of early product ideas and ensure efforts are aligned with
business objectives
- Assisting you to make informed decisions in selecting cancer indications
that are known to be appropriate for your drug's properties
- Analyzing, correlating and integrating valuable data sources in order to
provide accurate data for valuation of pipeline, in-licensing and new business
opportunities
- Providing you with commercial analytic support for due diligence on
in-licensing and acquisition opportunities
- Supporting development of integrative molecule, pathway and disease area
strategies
- Integrating knowledge for you to consider the therapeutic target for the
highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally
to PPP and to stakeholders across your own organization. The report will also
be an important part of creating and implementing a market development plan
for cancer drugs to insure that the optimal market conditions exist by the
time the products are commercialized.
Table of Contents
Key Topics Covered:
Part I: Breast Cancer
- 5.1 The Scope of this Report
- 6 Consider the Therapeutic Breast Cancer Target for the Highest
Therapeutic Outcome and Return on Investment (207 Drug Targets)
- 7 The Rise of New Products: How Mature, Unique and Clinically Validated
are the Drug Target Strategies Identified in the Breast Cancer Therapeutic
Pipeline? (193 Drug Target Strategies and 405 Drugs)
- 8 Compound Strategies at Work: Competitive Benchmarking of Breast Cancer
Drugs by Compound Strategy (8 Different Compound Strategies)
- 9 Pipeline and Portfolio Planning: Competitive Benchmarking of Breast
Cancer Therapeutic Pipeline by Investigator (220 Investigators)
- 11 Drug Index
- 12 Company Index
- Figures: Includes 7 Figures
- Tables: Includes 274 Tables
- Total Number of Pages: 913
Part II: Apoptosis
- 5.1 The Scope of this Report
- 6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for
the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets)
- 7 Emerging New Products to Established Ones: Drug Target Strategies of
Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug
Target Strategies and 234 Drugs)
- 8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic
Cancer Drugs by Compound Strategy(7 Compound Strategies)
- 9 Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer
Indications)
- 10 Pipeline and Portfolio Planning: Competitive Benchmarking of the
Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234
Drugs)
- Disclaimer
- 11 Drug Index
- 12 Company Index
- Figures: Includes 7 Figures
- Tables: Includes 315 Tables
- Total Number of Pages: 1,617
Part III: Cancer Vaccines
- 5.1 The Scope of this Report
- 6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the
Highest Therapeutic Outcome and Return on Investment (94 Drug Targets)
- 7 Emerging New Products to Established Ones: Drug Target Strategies of
Cancer Vaccine Drugs by their Highest Stage of Development (91 Drug Target
Strategies and 155 Cancer Vaccine Drugs)
- 8 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine
Drugs by Compound Strategy (7 Compound Strategies)
- 9 Selecting Cancer Indications for Cancer Vaccine Drugs (42 Cancer
Indications)
- 10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer
Vaccine Drug Pipeline by Investigator (99 Investigators)
- 11 Disclaimer
- 12 Drug Index
- 13 Company Index
- Figures: Includes 6 Figures
- Tables: Includes 205 Tables
- Total Number of Pages: 659
Featured Companies
This Report Includes the Following Companies:
- A&G Pharmaceutical
- Abbott
- Abiogen
- Abraxis BioScience
- AC Immune
- Access
- Adaptimmune
- Adherex
- Aduro BioTech
- Advanced Life Sciences
- Advaxis
- AEgera
- AEterna Zentaris
- Affibody
- Aida Pharmaceuticals
- Aileron Therapeutics
- Akela Pharma
- Alchemia
- Alethia Biotherapeutics
- Alnis Biosciences
- Alnylam
- AlphaVax
- Alseres Pharmaceuticals
- Ambrilia Biopharma
- Amgen
- Anadys Pharmaceuticals
- Anaphore
- Anavex Life Sciences
- AngioChem
- Antisoma
- Aphios
- Apogenix
- ApopLogic Pharmaceuticals
- Apthera
- Archer Biosciences
- Ariad
- Arno Therapeutics
- ArQule
- Array BioPharma
- Ascend Therapeutics
- Ascenta Therapeutics
- Astellas
- Astex Therapeutics
- AstraZeneca
- Attenuon
- AVI BioPharma
- Avila Therapeutics
- Basilea Pharmaceutica
- Bavarian Nordic
- Bayer
- Bellicum Pharmaceuticals
- Betagenon
- BioAlliance Pharma
- BioAxone
- Biocad
- Biogen Idec
- BioInvent
- BioLineRx
- Biomas
- Bionovo
- Biostar
- BioVex
- Boehringer Ingelheim
- Bristol-Myers Squibb
- BTG
- Cadila
- Callisto Pharmaceuticals
- Cancer Research Technology
- CDG Therapeutics
- Cel-Sci
- Celera
- Cell Genesys
- Cell Therapeutics
- Celldex Therapeutics
- Celsion
- Celtic Pharma
- Center of Molecular Immunology
- Cephalon
- CG Therapeutics
- ChemGenex Pharmaceuticals
- ChemoCentryx
- Chemokine Therapeutics
- Chiesi
- Chlorogen
- Chroma Therapeutics
- Cleveland BioLabs
- CombinatoRx
- CompleGen
- Coronado Biosciences
- Cosmo Pharmaceuticals
- Critical Outcome Technologies
- CSL
- Curis
- Cyclacel
- Cylene Pharmaceuticals
- Cynvec
- CytImmune Sciences
- Cytochroma
- Cytokinetics
- CytRx
- Daewoong
- Daiichi Sankyo
- Dainippon Sumitomo Pharma
- Debiopharm
- Dendreon
- DeveloGen
- Dong-A
- Dongkook Pharm
- Douglas
- ECI
- Eisai
- Elan
- Elara Pharmaceuticals
- Eleos
- Eli Lilly
- Emergent BioSolutions
- Endoceutics
- Enkam Pharmaceuticals
- EntreMed
- Enzon
- Epeius Biotechnologies
- EpiCept
- Erimos
- Eucodis
- Exelixis
- Fresenius
- Genentech
- Generex
- Genmab
- GenOdyssee Pharmaceuticals
- Genta
- GENTICEL
- GenVec
- Genzyme
- Gerolymatos
- Geron
- GlaxoSmithKline
- Gliknik
- GlobeImmune
- Gloucester Pharmaceuticals
- GlycoGenesys
- Glycotope
- GlyTag
- Got-a-Gene
- GPC Biotech
- Gradalis
- Green Cross
- Harbor BioSciences
- Heidelberg Pharma
- Hoffmann-La Roche
- Hospira
- Human Genome Sciences
- Ichor Medical Systems
- Idera Pharmaceuticals
- ImmunoCellular Therapeutics
- Immunocore
- ImmunoFrontier
- ImmunoGen
- Immunomedics
- Immunotope
- Immutep
- Incyte Corporation
- Inex
- Infinity Pharmaceuticals
- Innate Pharma
- InNexus Biotechnology
- Inovio
- Insmed
- Insys Therapeutics
- Intarcia Therapeutics
- Intezyne Technologies
- Intradigm
- Introgen Therapeutics
- Ipsen
- ISA Pharmaceuticals
- Isis Pharmaceuticals
- ISU ABXIS
- Johnson & Johnson
- Kalypsys
- Keryx Biopharmaceuticals
- Kiadis
- Kyowa Hakko Kirin
- LEAD Therapeutics
- Leo
- Ligand
- Lorus Therapeutics
- Marillion Pharmaceuticals
- MDRNA
- Meda
- Medarex
- Medical Marketing International
- MediGene
- MedImmune
- Mediolanum
- Medisyn Technologies
- Meiji
- Menarini
- Merck & Co
- Merck KGaA
- MethylGene
- Micromet
- MolMed
- Mologen
- NanoMed Pharmaceuticals
- Nektar Therapeutics
- Nemod Biotherapeutics
- NeoPharm
- Neovacs
- Nereus Pharmaceuticals
- Nerviano Medical Sciences
- NexGenix Pharmaceuticals
- Nidus Laboratories
- NIH
- Nippon Kayaku
- Nippon Shinyaku
- Non-industrial source
- Northwest Biotherapeutics
- Novacea
- NovaLead
- Novartis
- NovaRx
- Novelix
- Novogen
- OncoGenex Pharmaceuticals
- OncoMune
- Onconova
- OncoTherapy Science
- Oncothyreon
- Oncovir
- Onyvax
- Orion Pharma
- OSI Pharmaceuticals
- Oxford BioMedica
- OXiGENE
- Paladin Labs
- PanaGin
- Pantarhei Bioscience
- Patrys
- Pepscan Systems
- Pepscan Therapeutics
- PepTcell
- Peregrine Pharmaceuticals
- Pfizer
- Pharmacyclics
- PharmaGap
- PharmaMar
- Pharmexa
- Pharminox
- PheneX
- Philogen
- Pierre Fabre
- Plexxikon
- Prima Biomed
- Pro-Pharmaceuticals
- Progenics Pharmaceuticals
- ProMetic Life Sciences
- ProStrakan
- Protherics
- Protox Therapeutics
- PTC Therapeutics
- QLT
- R&R
- Radient Pharmaceuticals
- Raptor Pharmaceutical
- Reata Pharmaceuticals
- Receptor BioLogix
- Regeneron
- Regulon
- Repros Therapeutics
- responsif
- RESprotect
- Rigel
- Rosetta Genomics
- Samyang
- Sanofi
- Sanofi-Aventis
- Santaris Pharma
- Sareum
- Savient Pharmaceuticals
- SBI Biotech
- Scancell
- Schering-Plough
- SciClone Pharmaceuticals
- Seattle Genetics
- Selvita
- Semafore Pharmaceuticals
- Senesco Technologies
- Sigma-Tau
- SRI International
- SuperGen
- Supratek Pharma
- Switch Pharma
- SymBio Pharmaceuticals
- Symbiotec
- Taiho
- Takeda
- TapImmune
- Targa Therapeutics
- Tau Therapeutics
- Taxolog
- Telik
- TetraLogic Pharmaceuticals
- Teva
- Thallion Pharmaceuticals
- Therion Biologics
- Tigris Pharmaceuticals
- to-BBB
- TopoTarget
- Tracon Pharmaceuticals
- Tragara Pharmaceuticals
- Transgene
- Trion Pharma
- UMN Pharma
- United Biomedical
- Vaccinex
- ValiRx
- Vaxil BioTherapeutics
- Vaxon Biotech
- VaxOnco
- VBL Therapeutics
- Vectura
- Velacor Therapeutics
- Vernalis
- Vertex Pharmaceuticals
- Vical
- Wilex
- Vion Pharmaceuticals
- VioQuest
- Viragen
- Viralytics
- Virionics
- ViroMed
- ViroTarg
- VM Discovery
- Wyeth
- Xerion
- Xoma
- Yakult Honsha
- YM BioSciences
- Zensun
- Zhejiang Beta Pharma
- Zydus Cadila
Featured Drugs
A Shortlist of Drugs Included are:
- 131I-tositumomab
- ADXS11-001
- AE-37
- AEG-35156
- ALVAC-CEA/B7.1
- alvocidib
- AME-133
- anastrozole
- APG-101
- ARQ-197
- AS-101
- AS-1411
- astuprotimut-r
- AVX-701
- bardoxolone methyl
- belagenpumatucel-L
- belinostat
- bevacizumab
- bortezomib
- bosutinib
- BP-GMAX-CD1
- BSI-201
- BZL-101
- Cadi-05
- canfosfamide hydrochloride
- capecitabine
- catumaxomab
- CB-10-01
- CEA-TRICOM
- cenersen
- CG-201
- cintredekin besudotox
- CMLVAX-100
- conatumumab
- crolibulin
- CTL901
- CTP-37
- CVac
- DCVax-prostate
- denosumab
- dinaciclib
- docetaxel
- doxifluridine
- doxorubicin
- dulanermin
- E-75
- enzastaurin hydrochloride
- epirubicin
- everolimus
- exemestane
- fadrozole
- formestane
- fosbretabulin tromethamine
- fowlpox-PSA vaccine
- fulvestrant
- gataparsen
- goserelin
- GRNVAC1
- GT-111
- GV-1001
- GV-1002
- GVAX
- GVX-3322
- HE-3235
- Her-2/Neu peptides
- ibritumomab tiuxetan
- idronoxil
- IGN-101
- imatinib mesilate
- imetelstat
- ImmunoVEX tri-melan
- IMO-2055
- INGN-225
- interferon
- irinotecan hydrochloride
- kahalalide F
- lapatinib ditosylate
- lasofoxifene
- lestaurtinib
- letrozole
- leuprorelin
- litronesib
- lonaprisan
- lumiliximab
- MAGE-3-TK
- mapatumumab
- ME-103
- MGN-1601
- mitoxantrone
- MKC-1
- mocetinostat
- motexafin gadolinium
- MSI vaccine
- MVA-BN
- MVA-BN Her-2 vaccine
- navitoclax
- neratinib
- Norelin
- noscapine
- Nudoxa
- obinutuzumab
- oblimersen sodium
- ON-01910
- Oncohist
- Onyvax-105
- OTS-102
- paclitaxel
- panobinostat
- PANVAC-VF
- PAT-SC1
- pazopanib hydrochloride
- PBI-1402
- PCI-24781
- pDOM-PSMA27
- PEP-223
- pertuzumab
- pirarubicin
- plitidepsin
- poly-ICLC
- PR1:169-177 peptide
- PROSTVAC
- PX-104.1
- PX-12
- quarfloxacin
- quinacrine
- R-(-)-gossypol
- RAF-265
- raloxifene hydrochloride
- ramucirumab
- retaspimycin
- Reximmune-C
- rindopepimut
- sagopilone
- SAI-EGF
- seliciclib
- SPC-2996
- s-lapachone
- Stimuvax
- SU-6668
- sunitinib malate
- tamoxifen
- tegafur + uracil
- terameprocol
- TG-4001
- TG-4010
- thymalfasin
- tigapotide triflutate
- tigatuzumab
- tipifarnib
- TL-32711
- toremifene citrate
- trastuzumab
- triciribine phosphate
- trilostane
- triptorelin pamoate
- TroVax
- TRU-016
- TS-1
- verpasep caltespen
- volasertib
- vosaroxin
- VX-001
- XL-147
- XL-647
- ZYC-300
